Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

NCT05927857 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Gastric Adenocarcinoma
Second Line
Chemotherapy

Interventions

DRUG: nal-IRI /Experimental
DRUG: Ramucirumab /Experimental
DRUG: Trifluridine/Tipiracil /Experimental

Sponsor

National Health Research Institutes, Taiwan

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]